Luis Sepulveda-Maldonado, MD
Hematology & Oncology · Ponce, PRNPI 1598029381
Payments from drug & device makers
Across 729 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$2K
- AbbVie$2K
- AstraZeneca$2K
- Merck$1K
- plus $7K from 34 others
What the payments were for
- Consulting fees$2501%
- Food & beverage$15,16787%
- Education$4953%
- Other$1,5469%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $2,211 |
| E.r. Squibb & Sons, L.L.C. | 100 | $2,104 |
| Johnson & Johnson(2 entities) | 77 | $1,897 |
| AbbVie | 78 | $1,581 |
| AstraZeneca(2 entities) | 68 | $1,577 |
| Merck | 62 | $1,225 |
| Genentech USA, Inc. | 51 | $1,067 |
| Amgen | 46 | $923 |
| Eli Lilly Export S.A. Puerto Rico Branch | 36 | $883 |
| PBG Puerto Rico LLC | 33 | $682 |
| Sanofi | 24 | $533 |
| Bayer Puerto Rico Inc. | 15 | $334 |
| Sobi, Inc | 12 | $303 |
| Eisai Inc. | 14 | $293 |
| Apellis Pharmaceuticals, Inc. | 1 | $250 |
| Regeneron Healthcare Solutions, Inc. | 12 | $241 |
| Gilead | 6 | $158 |
| Abbott | 6 | $131 |
| Seagen Inc. | 2 | $116 |
| Caris MPI, Inc. | 4 | $88 |
| Boston Scientific | 1 | $83 |
| Taiho Oncology, Inc. | 4 | $82 |
| Astellas Pharma US Inc | 3 | $79 |
| Pharmaand GmbH | 3 | $75 |
| Pfizer | 3 | $64 |
| GSK | 3 | $59 |
| Bayer | 3 | $56 |
| Rigel Pharmaceuticals, Inc. | 2 | $53 |
| EMD Serono, Inc. | 2 | $40 |
| Beigene USA, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Adaptive Biotechnologies Corporation | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| Global Blood Therapeutics, Inc. | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Fennec Pharmaceuticals, Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Empaveli$250
How this compares
$17,458 in reported general payments places this provider in the 55th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 34 | $681,125 |
| RevlimidLenalidomide | 47 | $640,577 |
| IdhifaEnasidenib Mesylate | 16 | $550,823 |
| FabhaltaIptacopan Hcl | 11 | $502,739 |
| TagrissoOsimertinib Mesylate | 28 | $483,061 |
| CalquenceAcalabrutinib Maleate | 29 | $443,888 |
| ReblozylLuspatercept-Aamt | 21 | $246,084 |
| VenclextaVenetoclax | 15 | $233,396 |
| SprycelDasatinib | 15 | $199,743 |
| TavalisseFostamatinib Disodium | 13 | $193,859 |
| BrukinsaZanubrutinib | 12 | $184,897 |
| WeliregBelzutifan | 12 | $119,960 |
| JakafiRuxolitinib Phosphate | 13 | $113,189 |
| RetacritEpoetin Alfa-Epbx | 28 | $32,584 |
| Abiraterone Acetate | 30 | $28,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Fabhalta | $2,211 | $1,183,86445 claims |
| AstraZenecaTagrisso, Calquence | $1,577 | $926,94957 claims |
| E.r. Squibb & Sons, L.L.C.Reblozyl, Sprycel | $2,104 | $445,82636 claims |
| AbbVieVenclexta | $1,581 | $233,39615 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $53 | $193,85913 claims |
| Beigene USA, Inc.Brukinsa | $39 | $184,89712 claims |
| MerckWelireg | $1,225 | $119,96012 claims |
| PfizerRetacrit, Eliquis | $64 | $50,54456 claims |
| Johnson & JohnsonXarelto | $1,897 | $10,95219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Ponce
- Hector Velez CortesPonce$3.1M
- Anna di MarcoPonce$43K
- Jose CangianoPonce$34K
- Marynoll de la PazPonce$18K
- Mirelis AcostaSan Juan$6.3M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Maria Garcia PallasCaguas$1.8M
- Karina Arocho-GonzalezHato Rey$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.